Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


An Infographic Look At Trends In Korean Gene And Stem Cell Therapies

Executive Summary

South Korea has opened a new era with the recent granting of approval to the country's first gene therapy, for Kolon Life Science's osteoarthritis drug Invossa. (Also see "First Approval For Kolon's Invossa But No Disease-Modifying Status" - Scrip, 14 Jul, 2017.) Scrip takes a graphical look at the current state of the country's wider gene and stem cell therapy sector, one of the key biotech areas the government is nurturing.


Related Content

First Approval For Kolon's Invossa But No Disease-Modifying Status





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts